IP Library Granted Patent US 9,662,374
Granted Patent B2
US 9,662,374 · App. 15/048,647 · Granted May 30, 2017

Hemostatic compositions

Inventors: Christian Gagnieu (Chassieu, FR); Patricia Forest (Lyons, FR); Sylvain Picot (Lyons, FR)
Assignee: BIOM'UP
A61K38/39A61K9/14A61K38/36A61K38/4833A61K47/26A61L26/0033A61L2400/04C12Y304/21005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,662,374
App. No.
15/048,647
Granted
May 30, 2017
Kind
B2
Abstract

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Claims (51)

1. A hemostatic composition in powder form comprising:

collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, wherein the collagen is in an amount ranging from 80% to 93% by weight relative to the total weight of the composition;

at least one monosaccharide in an amount ranging from 2% to 8% by weight relative to the total weight of the composition;

at least one glycosaminoglycan in an amount ranging from 5% to 15% by weight relative to the total weight of the composition; and

at least one coagulation factor in an amount ranging from 0.01 IU/mg to 20 IU/mg of the composition.

2. The composition of claim 1 , wherein said composition has a collagen/monosaccharide weight ratio ranging from 10 to 50.

3. The composition of claim 1 , wherein the collagen comprises a content of fibrous collagen and/or fibrillar collagen ranging from 85% to 95% by weight relative to the total weight of the collagen.

4. The composition of claim 1 , wherein said composition has a collagen/total carbohydrate compounds weight ratio ranging from 2 to 40, wherein the weight of the total carbohydrate compounds is the sum of the weight of the at least one monosaccharide and the weight of the at least one glycosaminoglycan.

5. The composition of claim 1 , wherein the at least one coagulation factor comprises thrombin.

6. The composition of claim 1 , wherein said composition has a tapped density greater than 0.4 g/mL.

7. The composition of claim 1 , wherein said composition comprises at least 50% by weight of particles whose size is between 200 μm and 400 μm.

8. The composition of claim 1 , wherein

the collagen is in an amount of around 85% by weight relative to the total weight of the composition;

the at least one monosaccharide comprises glucose in an amount of around 4.9% by weight relative to the total weight of the composition;

the at least one glycosaminoglycan comprises chondroitin sulfate in an amount of around 10% by weight relative to the total weight of the composition; and

the at least one coagulation factor is thrombin in an amount ranging from 0.2 IU/mg to 2 IU/mg of the composition.

9. The composition of claim 1 , wherein the at least one coagulation factor is in an amount ranging from 0.05 IU/mg to 10 IU/mg of the composition.

10. The composition of claim 1 , wherein the at least one coagulation factor is in an amount ranging from 0.1 IU/mg to 5 IU/mg of the composition.

11. The composition of claim 1 , wherein said composition comprises a collagen/monosaccharide weight ratio of 19.

12. The composition of claim 1 , wherein

the at least one monosaccharide is selected from the group consisting of ribose, sucrose, fructose, glucose and mixtures thereof;

the at least one glycosaminoglycan is selected from the group consisting of chondroitin sulfate, dermatan sulfate, hyaluronic acid and mixtures thereof; and

the at least one coagulation factor is thrombin.

13. The composition of claim 1 , wherein said composition comprises particles whose size is below 200 μm.

14. The composition of claim 1 , wherein said composition comprises at least 50% by weight of particles whose size is below 200 μm.

15. A kit comprising:

the composition of claim 1 ; and

a spraying device.

16. A kit comprising:

the composition of claim 8 ; and

a spraying device.

17. A method for preparing a hemostatic composition of claim 1 comprising at least the following steps:

a) formation of an aqueous suspension of a composition comprising a collagen of fibrillar type having a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, wherein the collagen is present in an amount ranging from 80% to 93% by weight relative to the total weight of the composition, and at least one monosaccharide in an amount ranging from 2% to 8% by weight relative to the total weight of the composition,

b) recovery of the product formed in step a) in the form of precipitate, paste or gel,

c) drying of the product composition,

d) grinding of the product to the desired granulometry,

e) adding at least one glycosaminoglycan in an amount ranging from 5% to 15% by weight relative to the total weight of the composition and at least one coagulation factor in an amount ranging from 0.01 IU/mg to 20 IU/mg of the composition.

18. The method of claim 17 , wherein the collagen used in step a) is obtained by basic extraction.

19. The method of claim 17 , wherein in step e)

the coagulation factor is thrombin, and

the glycosaminoglycan is selected from the group consisting of chondroitin sulfate, dermatan sulfate, hyaluronic acid and mixtures thereof.

20. A method for treatment of a hemorrhaging subject comprising applying the composition of claim 1 to the hemorrhaging part of the subject.

21. A hemostatic composition in powder form comprising:

collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, wherein said collagen is present in an amount ranging from 89% to 93% by weight relative to the total weight of the composition;

at least one monosaccharide in an amount ranging from 2% to 8% by weight relative to the total weight of the composition;

at least one glycosaminoglycan in an amount ranging from 5% to 15% by weight relative to the total weight of the composition; and

at least one coagulation factor in an amount greater than 0% but lower than 0.1% by weight relative to the total weight of the composition.

22. The composition of claim 21 , wherein the at least one coagulation factor is in an amount greater than 0% but lower than 0.01% by weight relative to the total weight of the composition.

23. A kit comprising;

the composition of claim 21 ; and

a spraying device.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2023
From: BIOM'UP FRANCE SAS
To: DILON TECHNOLOGIES INC.
Reel/Frame 063779/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: BIOM'UP
To: BIOM'UP FRANCE SAS
Reel/Frame 055292/0061 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 050008/0859 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0653 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 045460/0084 AND 045865/0851 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0309 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 049816/0205 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0334 →
SECURITY INTEREST Recorded Aug 9, 2019
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 050008/0859 →
SECURITY INTEREST Recorded Jul 22, 2019
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 049816/0205 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 045460 FRAME: 0084. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Apr 9, 2018
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 045865/0851 →
SECURITY INTEREST Recorded Apr 6, 2018
From: BIOM'UP
To: ATHYRIUM OPPORTUNIIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 045460/0084 →
Priority Claims (1)
EP 11305492 · Apr 27, 2011 · regional
Continuity (3)
Continuation 14007798
Provisional Application 61517973 · Apr 27, 2011
Related Publication 20160166655A1 · Jun 16, 2016